ReviewNature medicine2021
Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases.
Review in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 242 citations in OpenAlex.
- Exploring the Mosquito-Arbovirus Network: A Survey of Vector Competence Experiments.The American journal of tropical medicine and hygiene · 2023Pooled it
- The pharmacological properties and corresponding mechanisms of farrerol: a comprehensive review.Pharmaceutical biology · 2022Pooled it
- Randomized single oral dose phase 1 study of safety, tolerability, and pharmacokinetics of Iminosugar UV-4 Hydrochloride (UV-4B) in healthy subjects.PLoS neglected tropical diseases · 2022Trial
- Cereblon promotes influenza A virus replication through AMPK ubiquitination.Biochemistry and biophysics reports · 2026Article
- Integrating mathematical modelling and artificial intelligence to combat emerging viral syndemics: A systematic review.New microbes and new infections · 2026Review
- Host nucleolin-targeting unique peptide drugs as potent broad-spectrum anti-influenza therapies.PNAS nexus · 2026Article
- The Synergy of Macrocycles and Heterocycles: A Review of Coordination Behavior, Sensing, and Functional Materials Based on Calixarenes.Molecules (Basel, Switzerland) · 2026Review
- Mechanistic insights into the association and activation of the SARS-CoV-2 2'-O-Methyltransferase (NSP16).bioRxiv : the preprint server for biology · 2026Article
- Antagonistic Ubiquitin Switching by USP7 and RNF40 Orchestrates KDM6A Homeostasis to License Coronavirus Susceptibility.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Antiviral drug discovery and development: challenges and future directions.Signal transduction and targeted therapy · 2026Review
- 3D alginate hydrogel microspheres with uniform micro-structure for cell culture and CVB3 infection.Mikrochimica acta · 2026Article
- GeoGAD: geometry-aware antibody design framework for complementarity-determining region precision engineering.Bioinformatics (Oxford, England) · 2026Article
- Antiviral Properties of Green-Synthesized Silver and Zinc Oxide Nanoparticles Against Coronaviruses: A Review.International journal of microbiology · 2026Review
- PoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike-ACE2 interaction and protecting lung tissue.Frontiers in pharmacology · 2026Article
- Trends, Gaps, and Challenges in Antiviral Resistance: A Bibliometric Analysis and Narrative Synthesis of Key Viruses, Resistance Mechanisms, and Drivers.BioMed research international · 2026Article
- Trivalent mRNA-LNP Vaccine Induces Robust Humoral and Cellular Immunity in Mice: Preclinical Evaluation for Porcine Enteric Coronaviruses.International journal of nanomedicine · 2026Article
- DABPU-DE targeting host adipose triglyceride lipase provides broad-spectrum anti-coronavirus effectsFrontiers in pharmacology · 2026Article
- Viral RNA-Targeting Locked Nucleic Acid Gapmers: Design and In Vitro Evaluation.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Preclinical testing of antiviral siRNA therapeutics delivered in lipid nanoparticles in animal models - a comprehensive review.Drug delivery and translational research · 2025Review
- UBXN7 facilitates SARS-CoV-2 replication via inhibiting the K48-linked ubiquitination of viral N protein.PLoS pathogens · 2025Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The twenty-first century has already recorded more than ten major epidemic or pandemic virus emergence events, including the ongoing and devastating coronavirus disease 2019 (COVID-19) pandemic. As viral disease emergence is expected to accelerate, these data dictate a need for proactive approaches to develop broadly active family-specific and cross-family therapeutics for use in future disease outbreaks. Emphasis should focus not only on the development of broad-spectrum small-molecule and antibody direct-acting antivirals, but also on host-factor therapeutics, including repurposing previously approved or in-pipeline drugs. Another new class of therapeutics with great antiviral therapeutic potential is RNA-based therapeutics. Rather than only focusing on known risks, dedicated efforts must be made toward pre-emptive research focused on outbreak-prone virus families, ultimately offering a strategy to shorten the gap between outbreak and response. Emphasis should also focus on orally available drugs for outpatient use, if possible, and on identifying combination therapies that combat viral and immune-mediated pathologies, extend the effectiveness of therapeutic windows and reduce drug resistance. While such an undertaking will require new vision, dedicated funding and private, federal and academic partnerships, this approach offers hope that global populations need never experience future pandemics such as COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.